Illustrative image – not actual.The Union Cabinet, chaired by Prime Minister Narendra Modi, has approved Production Linked Incentive (PLI) Scheme for pharmaceuticals over a period of FY21 to FY29.
The scheme will benefit domestic manufacturers, help in creating employment and is expected to contribute to the availability of wider range of affordable medicines for consumers.
The scheme is expected to promote production of high value products in the country and increase value addition in exports. Total incremental sales of Rs 2,94,000 crore and total incremental exports of Rs 1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
The scheme is expected to generate employment for both skilled and un-skilled personnel, estimated at 20,000 direct and 80,000 indirect jobs as a result of growth in the sector.
It is expected to promote innovation for development of complex and high-tech products including products of emerging therapies and in-vitro diagnostic devices as also self-reliance in important drugs.
It is also expected to improve accessibility and affordability of medical products including orphan drugs to the Indian population. The scheme is also expected to bring in investment of Rs 15,000 crore in the pharmaceutical sector.
The objective of the scheme is to enhance India's manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high value goods in the pharmaceutical sector.
One of the further objectives of the scheme is to create global champions out of India who have the potential to grow in size and scale using cutting edge technology and thereby penetrate the global value chains.
The scheme will cover pharmaceutical goods under three categories as Category 1 -- biopharmaceuticals; complex generic drugs; patented drugs or drugs nearing patent expiry; cell-based or gene therapy drugs; orphan drugs; special empty capsules like HPMC, Pullulan, enteric, etc.; complex excipients; Phyto-pharmaceuticals; other drugs as approved.
Category 2--active pharmaceutical ingredients/key starting materials/drug intermediates.
Category 3 (drugs not covered under Category-1 and Category-2) -- repurposed drugs; auto immune drugs, anti-cancer drugs, anti-diabetic drugs, anti-infective drugs, cardiovascular drugs, psychotropic drugs and anti-retroviral drugs; In vitro diagnostic devices; other drugs as approved; other drugs not manufactured in India.
The rate of incentive will be 10 percent (of incremental sales value) for Category-1 and Category-2 products for first four years, eight percent for the fifth year and six percent for the sixth year of production under the scheme.
The rate of incentive will be five percent (of incremental sales value) for Category-3 products for first four years, four percent for the fifth year and three percent for the sixth year of production under the scheme.
The duration of the scheme will be from FY21 to FY29. This will include the period for processing of applications (FY21), optional gestation period of one year (FY22), incentive for six years and FY29 for disbursal of incentive for sales of FY28.
The scheme will benefit domestic manufacturers, help in creating employment and is expected to contribute to the availability of wider range of affordable medicines for consumers.
The scheme is expected to promote production of high value products in the country and increase value addition in exports. Total incremental sales of Rs 2,94,000 crore and total incremental exports of Rs 1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
The scheme is expected to generate employment for both skilled and un-skilled personnel, estimated at 20,000 direct and 80,000 indirect jobs as a result of growth in the sector.
It is expected to promote innovation for development of complex and high-tech products including products of emerging therapies and in-vitro diagnostic devices as also self-reliance in important drugs.
It is also expected to improve accessibility and affordability of medical products including orphan drugs to the Indian population. The scheme is also expected to bring in investment of Rs 15,000 crore in the pharmaceutical sector.
The objective of the scheme is to enhance India's manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high value goods in the pharmaceutical sector.
One of the further objectives of the scheme is to create global champions out of India who have the potential to grow in size and scale using cutting edge technology and thereby penetrate the global value chains.
The scheme will cover pharmaceutical goods under three categories as Category 1 -- biopharmaceuticals; complex generic drugs; patented drugs or drugs nearing patent expiry; cell-based or gene therapy drugs; orphan drugs; special empty capsules like HPMC, Pullulan, enteric, etc.; complex excipients; Phyto-pharmaceuticals; other drugs as approved.
Category 2--active pharmaceutical ingredients/key starting materials/drug intermediates.
Category 3 (drugs not covered under Category-1 and Category-2) -- repurposed drugs; auto immune drugs, anti-cancer drugs, anti-diabetic drugs, anti-infective drugs, cardiovascular drugs, psychotropic drugs and anti-retroviral drugs; In vitro diagnostic devices; other drugs as approved; other drugs not manufactured in India.
The rate of incentive will be 10 percent (of incremental sales value) for Category-1 and Category-2 products for first four years, eight percent for the fifth year and six percent for the sixth year of production under the scheme.
The rate of incentive will be five percent (of incremental sales value) for Category-3 products for first four years, four percent for the fifth year and three percent for the sixth year of production under the scheme.
The duration of the scheme will be from FY21 to FY29. This will include the period for processing of applications (FY21), optional gestation period of one year (FY22), incentive for six years and FY29 for disbursal of incentive for sales of FY28.
